Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl.

The monoamine oxidase inhibitor L-deprenyl [(-)-deprenyl, selegiline] is an effective therapeutic agent for improving early symptoms of idiopathic Parkinson's disease. It appears to exert this action independently of its inhibition of monoamine oxidase B (MAO-B) and some of its metabolites are thought to contribute. Cytochrome P450 (CYP) activities are known to give rise to L-deprenyl metabolites that may affect the dopaminergic system. In order to clarify the interactions of L-deprenyl with these enzymes, C57BL mice were treated with L-deprenyl, ethanol, phenobarbital or beta-naphthoflavone to induce different CYP isozymes. After preincubation of L-deprenyl with liver microsomes from control or treated mice, the metabolites were analysed by a GLC method. L-deprenyl (10 mg/kg i.p. for 3 days) caused a significant decrease in total CYP levels (0.315+/-0.019, L-deprenyl; 0.786+/-0.124, control, nmol/mg protein) and CYP2E1-associated p-nitrophenol hydroxylase activity (0.92+/-0.04 vs. 1.17+/-0.06 nmol/min/mg). Both phenobarbital and ethanol increased the N-depropynylation activity towards L-deprenyl that leads to the formation of methamphetamine (4. 11+/-0.64, phenobarbital; 4.77+/-1.15, ethanol; 1.77+/-0.34, control, nmol/min/mg). Ethanol alone increased the N-demethylation rate of L-deprenyl, that results in formation of nordeprenyl (3.99+/-0.68, ethanol; 1.41+/-0.31, control, nmol/min/mg). Moreover, the N-dealkylation pathways of deprenyl are inhibited by 4-methylpyrazole and disulfiram, two CYP2E1 inhibitors. None of the other treatments modified L-deprenyl metabolism. These findings indicate that mainly CYP2E1 and to a lesser extent CYP2B isozymes are involved in L-deprenyl metabolism. They also suggest that, by reducing CYP content, L-deprenyl treatment may impair the metabolic disposition of other drugs given in combination regimens.

[1]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[2]  T. Yoshida,et al.  Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  M. Ingelman-Sundberg,et al.  Hormonal regulation of microsomal cytochrome P4502E1 and P450 reductase in rat liver and kidney. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  P. Hollenberg,et al.  Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[5]  J. Gaál,et al.  Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2'-methyl-MPTP. , 1994, Journal of neural transmission. Supplementum.

[6]  W. Tatton,et al.  Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism , 1991, Journal of neuroscience research.

[7]  A. Lees,et al.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease , 1995, BMJ.

[8]  Vilho Myllylä,et al.  Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease , 1998, Drug safety.

[9]  H. Shin,et al.  Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[10]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[11]  A. Cederbaum,et al.  Inhibition of microsomal oxidation of ethanol by pyrazole and 4-methylpyrazole in vitro. Increased effectiveness after induction by pyrazole and 4-methylpyrazole. , 1986, The Biochemical journal.

[12]  C. S. Yang,et al.  Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. , 1991, Toxicology and applied pharmacology.

[13]  P. Riederer,et al.  Pharmacology of selegiline , 1996, Neurology.

[14]  L. A. Reinke,et al.  p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[15]  D. Waxman,et al.  Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms. , 1992, The Journal of biological chemistry.

[16]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[17]  Keith F Tipton,et al.  What is it that l‐deprenyl (selegiline) might do? * , 1994, Clinical pharmacology and therapeutics.

[18]  J. Whitlock,et al.  Induction of Cytochrome P450 Enzymes That Metabolize Xenobiotics , 1995 .

[19]  W. Tatton.  Modulation of gene expression rather than monoamine oxidase inhibition , 1996, Neurology.

[20]  L. Bertilsson,et al.  CYP2D6 polymorphism is not crucial for the disposition of selegiline , 1998, Clinical pharmacology and therapeutics.

[21]  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry , 1998, BMJ.

[22]  W. Tatton,et al.  Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.

[23]  Takemi Yoshida,et al.  Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  A. D. Rodrigues,et al.  Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P-450. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  L. Bianchi,et al.  The effects of ethanol on rat brain monoamine oxidase activities. , 1994, Journal of neural transmission. Supplementum.

[26]  K. Snell,et al.  Biochemical toxicology : a practical approach , 1987 .

[27]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[28]  C. Olanow,et al.  l‐(−)‐Desmethylselegiline, a Metabolite of Selegiline [l‐(−)‐Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro , 1997, Journal of neurochemistry.

[29]  P. Thomas,et al.  Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. , 1993, Biochemical pharmacology.

[30]  J. Langston,et al.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. , 1989, Science.

[31]  M. Kinter,et al.  Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. , 1994, Chemical research in toxicology.

[32]  S. Imaoka,et al.  Cytochrome P450 in Rodents , 1993 .

[33]  A. H. Phillips,et al.  Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. , 1962, The Journal of biological chemistry.